Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).

Rita Mazza, MD, Stefano Luminari, Massimo Magagnoli, MD, Michele Spina, MD, Teodoro Chisesi, MD, Antonio Pinto, MD, Massimo Federico, MD, Antonella Anastasia, MD, Arturo Chiti, MD, Mariagrazia Michieli, MD, Francesco Angrilli, MD, Luca Castagna, Giampaolo Marcacci, Laura Giordano, PhD, Umberto Tirelli, MD, Armando Santoro, Monica Balzarotti

Blood (2009) 114 (22): 3707.

https://doi.org/10.1182/blood.V114.22.3707.3707

Published: 2009

Journal Articles

Long Term Follow-up Analysis of HD9601 Trial Comparing ABVD Vs Stanford V Vs MOPPABVCAD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. A Study from the Intergruppo Italiano Linfomi (IIL)

Teodoro Chisesi, MD, Monica Bellei, Stefano Luminari, MD, Luigi Marcheselli, Alessandro Levis, MD, Umberto Vitolo, MD, Caterina Stelitano, MD, Vincenzo Pavone, MD, Francesco Merli, MD, Marina Liberati, MD, Luca Baldini, MD, Roberto Bordonaro, MD, Emanuela Pesce, Paolo Gobbi, MD, Massimo Federico, MD

Blood (2008) 112 (11): 2602.

https://doi.org/10.1182/blood.V112.11.2602.2602

Published: 2008

Journal Articles

Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.

Renato Bassan, MD, Orietta Spinelli, BSc, Elena Oldani, BSc, Tamara Intermesoli, MD, Manuela Tosi, BSc, Barbara Peruta, BSc, Vittoria Guerini, BSc, Giuseppe Rossi, MD, Enrico Pogliani, MD, Eros Di Bona, MD, Pietro Fabris, MD, Agostino Cortelezzi, MD, Teodoro Chisesi, MD, Emanuele Angelucci, MD, Franco Leoni, MD, Fabio Ciceri, MD, Daniele Mattei, MD, Tiziano Barbui, MD, Alessandro Rambaldi, MD

Blood (2007) 110 (11): 3497.

https://doi.org/10.1182/blood.V110.11.3497.3497

Published: 2007

Journal Articles

Comparison between 2-Deoxy-2-[18f]Fluoro-D-Glucose Positron Emission (FDG-PET) and Computed Tomography (CT) for Staging of Patients with Hodgkin’s Lymphoma (HL).

Luigi Rigacci, MD, Francesco Merli, MD, Antonio Castagnoli, MD, Annibale Versari, MD, Luca Nassi, MD, Ida Capodanno, MD, Teodoro Chisesi, MD, Andrea Gallamini, MD, Alberto Biggi, MD, Umberto Vitolo, MD, Silvia Tavera, MD, Rosaria Sancetta, MD, Patrizia Pregno, MD, Francesca Salvi, MD, Ettore Pelosi, MD, Alessandro Levis, MD, Alberto Bosi, MD.

Blood (2005) 106 (11): 975.

https://doi.org/10.1182/blood.V106.11.975.975

Published: 2005

Journal Articles

Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin’s Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue.

Monica Balzarotti, MD, Michele Spina, MD, Massimo Magagnoli, MD, Teodoro Chisesi, MD, Antonello Pinto, MD, Luca Castagna, MD, Monica Demarco, MD, Mariagrazia Michieli, MD, Andrea Nozza, MD, Umberto Tirelli, MD, Armando Santoro, MD

Blood (2005) 106 (11): 2091.

https://doi.org/10.1182/blood.V106.11.2091.2091

Published: 2005

Journal Articles

A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).

Sergio Cortelazzo, MD, Stefano Luminari, MD, Monica Bellei, PhD, Maurizio Martelli, MD, Umberto Vitolo, MD, Luigi Rigacci, MD, Achille Ambrosetti, MD, Enrico Pogliani, MD, Teodoro Chisesi, MD, Giorgio Rossi, MD, Andrea Rossi, MD, Alessandro Rambaldi, MD, Tiziano Barbui, MD, Maura Brugiatelli, MD, Massimo Federico

Blood (2004) 104 (11): 3261.

https://doi.org/10.1182/blood.V104.11.3261.3261

Published: 2004

NARROW

Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).

Long Term Follow-up Analysis of HD9601 Trial Comparing ABVD Vs Stanford V Vs MOPPABVCAD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. A Study from the Intergruppo Italiano Linfomi (IIL)

Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.

Comparison between 2-Deoxy-2-[18f]Fluoro-D-Glucose Positron Emission (FDG-PET) and Computed Tomography (CT) for Staging of Patients with Hodgkin’s Lymphoma (HL).

Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin’s Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue.

A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).

Email alerts

ASH Publications

American Society of Hematology

Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).

Long Term Follow-up Analysis of HD9601 Trial Comparing ABVD Vs Stanford V Vs MOPPABVCAD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. A Study from the Intergruppo Italiano Linfomi (IIL)

Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.

Comparison between 2-Deoxy-2-[18f]Fluoro-D-Glucose Positron Emission (FDG-PET) and Computed Tomography (CT) for Staging of Patients with Hodgkin’s Lymphoma (HL).

Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin’s Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue.

A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only